RxDoctor Payments Data

Bruce Iteld, MD

Cardiology · Slidell, LANPI 1588600894

Payments from drug & device makers

$2,224,049in general payments, 2019–2025

Across 2,072 payments — averaging $1073.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$729K
  • Novartis$566K
  • Novo Nordisk AS$441K
  • H. Lundbeck A S$116K
  • AstraZeneca$67K
  • Eli Lilly$45K
  • plus $261K from 53 others
$10,606in research payments, 2019–2025

Across 4 payments — averaging $2651.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$9K
  • Eli Lilly$2K

What the payments were for

  • Consulting fees$6301%
  • Speaking & faculty fees$67,57180%
  • Travel & lodging$4,2745%
  • Food & beverage$11,43314%
  • Education$1690%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen135$728,821
Novartis181$565,849
Novo Nordisk AS993$440,887
H. Lundbeck A S35$115,738
AstraZeneca33$66,549
Eli Lilly6$44,973
American Regent13$43,598
Boehringer Ingelheim International GmbH96$36,956
Boehringer Ingelheim Pharma GmbH & Co.kg9$26,500
Novo Nordisk45$20,732
Bayer17$20,460
Kowa Research Institute, Inc.21$17,041
Merck39$16,668
Regeneron33$16,498
Esperion Therapeutics, Inc.28$15,643
E.r. Squibb & Sons, L.L.C.32$13,956
Amarin Pharma, Inc.43$11,975
Astrazeneca UK Limited2$9,354
Janssen Research & Development, LLC4$6,009
Pfizer114$1,197
Boehringer Ingelheim17$1,180
Johnson & Johnson58$803
Medtronic(2 entities)26$693
Sanofi-aventis U.S. LLC20$305
Abbott8$287
Scpharmaceuticals Inc.8$143
Astellas Pharma US Inc2$118
Kowa Pharmaceuticals America, Inc.6$89
Actelion Pharmaceuticals US, Inc.3$85
Angiodynamics, Inc.1$81
Boston Scientific4$74
GE HealthCare2$67
Bridgebio Pharma, Inc.3$55
Davol Inc.1$53
Kiniksa Pharmaceuticals, Ltd.3$50
GSK3$45
Itamar Medical Inc1$39
Kiniksa Pharmaceuticals International, PLC2$39
Impulse Dynamics (USA) Inc.2$37
Lundbeck LLC2$36
Abiomed1$35
Amryt Pharma Holdings Ltd2$34
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)2$33
Nuwellis, Inc.1$28
Tactile Systems Technology Inc1$23
Silk Road Medical, Inc.1$23
Biotronik Inc.1$18
Terumo Medical Corporation1$18
Seqirus USA Inc1$18
Regeneron Healthcare Solutions, Inc.1$18
Lilly USA, LLC1$17
Elutia, Inc.1$17
Inspire Medical Systems, Inc.1$16
Azurity Pharmaceuticals, Inc.1$14
Sanofi Pasteur Inc.1$14
Baxter Healthcare1$14
Gilead1$14
Irhythm Technologies, Inc.1$12
Bardy Diagnostics, Inc.1$5

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cardiology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$526,951
Medicare patients
1,140
Services billed
9,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban544$534,162
OzempicSemaglutide205$219,761
Repatha SureclickEvolocumab264$190,670
EntrestoSacubitril/Valsartan171$189,829
MounjaroTirzepatide143$160,653
XareltoRivaroxaban176$145,213
FarxigaDapagliflozin Propanediol112$102,379
JardianceEmpagliflozin84$86,168
VascepaIcosapent Ethyl160$83,496
Repatha PushtronexEvolocumab76$60,498
NexlizetBempedoic Acid/Ezetimibe75$57,033
MultaqDronedarone Hcl19$33,499
BrilintaTicagrelor44$31,740
Droxidopa39$29,370
TrulicityDulaglutide31$28,022

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,197$534,162544 claims
Novo NordiskOzempic, Wegovy$20,732$244,266224 claims
NovartisEntresto$565,849$189,829171 claims
Lilly USA, LLCMounjaro, Trulicity$17$188,675174 claims
Johnson & JohnsonXarelto$803$145,213176 claims
AstraZenecaFarxiga, Brilinta$66,549$134,120156 claims
Boehringer IngelheimJardiance$1,180$86,16884 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$15,643$77,447108 claims
Sanofi-aventis U.S. LLCMultaq$305$33,49919 claims
MerckVerquvo, Januvia$16,668$21,30130 claims
AmgenCorlanor$728,821$18,34132 claims
GSKTrelegy Ellipta$45$10,76211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other cardiology in Slidell

Where these figures come from

Is this you, or does something look wrong? →